Sub brand
ic_arrow-back-to-top

Neural networks and other machine learning models have recently been applied to many biological problems, including drug discovery and biomarker development. Deep neural networks, combined with domain expertise, can design large, virtual chemical libraries of de novo drug-like compounds and efficiently screen them in silico to produce lead-like molecules in record time.

By attending this webinar, you'll learn:
  • the applications of deep adversarial networks and reinforcement learning for molecular de novo design and biomarker research;
  • Insilico’s drug discovery pipeline and platforms; and
  • machine learning applications for preclinical drug discovery.

ON DEMAND WEBINAR REGISTRATION

THANK YOU FOR REGISTERING FOR THE WEBINAR

You will receive an email with instructions on how to join the webinar shortly.

Main Content

maincontent goes here

Content

Content goes here

Content

content goes here

main image description

Content

Content goes here

Content

DGX Station Datasheet

Get a quick low-down and technical specs for the DGX Station.
DGX Station Whitepaper

Dive deeper into the DGX Station and learn more about the architecture, NVLink, frameworks, tools and more.
DGX Station Whitepaper

Dive deeper into the DGX Station and learn more about the architecture, NVLink, frameworks, tools and more.

Content

Content goes here

Speakers

Alex Zhavoronkov, PhD

Founder and CEO, Insilico Medicine, Inc.

Prof. Zhavoronkov is the founder and CEO of Insilico Medicine, a leader in the next-generation artificial intelligence for drug discovery, biomarker development, and aging research. Prior to Insilico, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI. Since 2012 he published over 130 peer-reviewed research papers and 2 books. For 6 years in a row he organizes the annual Aging Research for Drug Discovery and Artificial Intelligence for Healthcare forums at Basel Life/EMBO in Basel. Alex Zhavoronkov is an adjunct professor at the Buck Institute for Research on Aging.

Alex Zhebrak

CTO, Insilico Medicine, Inc.

Alex is an experienced engineering leader with extensive computer science and machine learning backgrounds. He is the ex-lead at the infrastructure & automation department at Mail.Ru, the largest European Internet company. Alex has co-authored several academic papers and MOOCs on programming and machine learning.

Polina Mamoshina

Senior Researcher, Insilico Medicine, Inc.

Polina Mamoshina is a senior research scientist at Insilico Medicine, Inc, Rockville-based bioinformatics and deep learning company focused on reinventing drug discovery and biomarker development and a part of the computational biology team of Oxford University Computer Science Department. Her primary research interests include artificial intelligence, deep learning, biomarkers of ageing and disease and drug responses, healthcare data management, healthcare data economy. Polina is involved in multiple deep learning projects at the Pharmaceutical Artificial Intelligence division of Insilico Medicine working on the drug discovery engine and developing biochemistry, transcriptome, and cell-free nucleic acid-based biomarkers of ageing and disease.

Add Presenter 4's Name (John Smith)
Add Presenter 4's Title (ex: CMO, ABC Company)

Add Presenter 4's Bio (2-3 Sentences)
Text here
Text here

Content Title

Content here

Register

Webinar: Description here

Date & Time: Wednesday, April 22, 2018